Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Agenus announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab plus balstilimab in MSS metastatic colorectal cancer will be presented at the ESMO GI 2026 Congress in Munich. The data reflect an additional year of follow-up from the fully enrolled 123-patient cohort, updating the two-year overall survival findings presented in 2025. Dr. Benjamin L.
Key figures
- Phase Of Trial
- Phase 1b
- Patient cohort size
- 123
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.